Preview

Медицинская визуализация

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Только для подписчиков

Рентгеноконтрастные вещества: фокус на безопасность

https://doi.org/10.24835/1607-0763-2018-5-94-105

Полный текст:

Аннотация

В статье представлена современная классификация рентгеноконтрастных средств, обсуждаются преимущества и недостатки йодсодержащих контрастов. Рассмотрены основные, наиболее часто встречающиеся нежелательные реакции, возникающие в ответ на введение рентгеноконтрастного препарата, – реакции гиперчувствительности, поражение щитовидной железы, нефропатия.

Об авторах

А. Л. Хохлов
ФГБОУ ВО “Ярославский государственный медицинский университет”
Россия
член-корр. РАН, доктор мед. наук, профессор, заведующий кафедрой клинической фармакологии


А. В. Кабанов
ФГБОУ ВО “Ярославский государственный медицинский университет”
Россия

канд. мед. наук, ассистент кафедры клинической фармакологии

150063 Ярославль, ул. Труфанова, д. 21, кв. 16

+7-903-691-22-81



О. Г. Козлова
ФГБОУ ВО “Ярославский государственный медицинский университет”
Россия
канд. мед. наук, доцент кафедры терапии педиатрического факультета


Список литературы

1. Применение контрастных препаратов при проведении рентгенологических исследований. Методические рекомендации. А.И. Громов, С.К. Терновой, А.Ю. Васильев, В.Ю. Босин, В.Е. Синицин, Г.Г. Кармазановский, И.В. Сидоренко, С.П. Морозов, Е.А. Евдокимов, Я.А. Лубашев, А.А. Михайлов, И.В. Кринина. М., 2013. 15 с.

2. Основы и принципы лучевой диагностики: Учебно-методическое пособие. А.И. Алешкевич, В.В. Рожковская, И.И. Сергеева, Т.Ф. Тихомирова, Г.А. Алесина. Минск: БГМУ, 2015. 86 с.

3. Контрастные средства для лучевой диагностики: Руководство. Г.Г. Кармазановский, Н.Л. Шимановский.М.: ГЭОТАР Медиа, 2013. 560 с.

4. Andreucci M., Faga T., Pisani A., Sabbatini M., Russo D., Michael M. Prevention of Contrast-Induced Nephropathy through a Knowledge of Its Pathogenesis and Risk Factors. Scientific Wld J. 2014; 2014: 1–16. DOI: 10.1155/2014/823169.

5. Katzberg R.W. Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity. Radiology.1997; 204 (2): 297–312. DOI: 10.1148/radiology.204.2.9240511.

6. Andreucci M., Solomon R., Tasanarong A. Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention. BioMed Res. Int. 2014; 2014: 1–20. DOI:10.1155/2014/741018.

7. Andreucci M., Faga T., Pisani A., Sabbatini M., Michael A. Acute kidney injury by radiographic contrast media: pathogenesis and prevention. BioMed. Res. Int. 2014; 1 (1): 1–6. DOI: 10.1155/2014/362725.

8. Стрекалов И.М., Козлов В.А., Ларионов Л.П., Кернесюк Н.Л., Зуев М.Г. Экспериментальная оценка танталовых рентгеноконтрастных средств. Екатеринбург: УрОРАН, 2006: 24–40.

9. Стрекалов И.М., Ларионов Л.П., Зуев М.Г., Крохина Н.Б. Перспективы использования нейодистых рентгено-контрастных средств. Вестник рентгенологии и радиологии. 2007; 1: 45–54.

10. Thomson K.R., Varma D.K. Safe use of radiographic contrast media. Australian Prescriber. 2010; 33 (1): 19–22. DOI: 10.18773/austprescr.2010.006.

11. Loh S., Bagheri S., KatzbergR.W., FungM.A., Li C. Delayed adverse reaction to contrast-enhanced CT: a prospective single-center study comparison to control group without enhancement. Radiology. 2010; 255 (3): 764–771. DOI: 10.1148/radiol.10091848.

12. Schild H.H., Kuhl C.K., Hubner-Steiner U., Bohm I., Speck U. Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: a prospective randomized controlled trial. Radiology. 2006; 240 (1): 56–64. DOI: 10.1148 /radiol.2393050560.

13. Sendeski M.M. Pathophysiology of renal tissue damage by iodinated contrast media. Clin. Exp. Pharmacol. Physiol. 2011; 38 (5): 292–299. DOI: 10.1111/j.1440-1681.2011.05503.x.

14. Molen A.J., Thomsen H.S., Morcos S.K. Effect of iodinated contrast media on thyroid function in adults. Eur. Radiol. 2004; 14 (5): 902–907. DOI: 10.1007/s00330-004-2238-z.

15. Katzberg R.W., Haller C. Contrast-induced nephrotoxicity: clinical landscape. Kidney Int. Suppl. 2006; 69: 3–7. DOI: 10.1038/sj.ki.5000366.

16. Trumbo P., Yates A.A., Schlicker S., Poos M. Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J. Am. Dietetic Assoc. 2001; 101 (3): 294–301. DOI: 10.1016/S0002-8223(01)00078-5.

17. Martins M.C., Lima N., Knobel M., Medeiros-Neto G. Natural course of iodine-induced thyrotoxicosis (Jodbasedow) in endemic goiter area: a 5 year follow-up. J. Endocrinol. Invest. 1989; 12 (4): 239–244. DOI.org/10.1007/BF03349973.

18. Burgi H. Iodine excess. Best Practice and Research: Clin. Endocrinol. Metabolism. 2010; 24 (1): 107–115. DOI: 10.1016/j.beem.2009.08.010.

19. Rhee C.M., Bhan I., Alexander E.K., Brunelli S.M. Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism. Archives Int. Med. 2012; 172 (2): 153–159. DOI 10.1001/archinternmed.2011.677.

20. Heyman S.N., Rosenberger C., Rosen S., Khamaisi M. Why Is Diabetes Mellitus a Risk Factor for Contrast-Induced Nephropathy? Hindawi Publishing Corporation. BioMed Res. Int. 2013; 2013: 1–8. DOI:10.1155/2013/123589.

21. Schilp J., de Blok C., Langelaan M., Spreeuwenberg P., Wagner C. Guideline adherence for identification and hydration of high-risk hospital patients for contrastinduced nephropathy. BMC Nephrol. 2014; 15 (1): 2. DOI: 10.1186/1471-2369-15-2.

22. Barrett B.J., Parfrey P.S. Clinical practice. Preventing nephropathy induced by contrast medium. N. Engl. J. Med. 2006; 354 (4): 379–386. DOI: 10.1056/NEJMcp050801.

23. Harjai K.J., Raizada A., Shenoy C., Sattur S., Orshaw P., Yaeger K., Boura J., Aboufares A., Sporn D., Stapleton D. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. Am. J. Cardiol. 2008; 101 (6): 812–819. DOI: 10.1016/j.amjcard.2007.10.051.

24. KIDGO. Clinical practice guideline for acute kidney, injury. Kidney Int Suppl. 2012; 2: 116–121. DOI: 10.1038/kisup.2012.1.

25. Каюков И.Г. Рентгеноконтрастная нефропатия. М.: ГОЭТАР-Медиа, 2009. 720 с.

26. Контраст-индуцированные нефропатии (Фармакология рентгеноконтрастных средств). В.А. Раптанова, А.А. Сперанская, С.Н. Прошин. М.: ПЕДИАТР, 2016; 7 (1): 97–105.

27. Клинические рекомендации по профилактике, диагностике и лечению контраст-индуцированной нефропатии. Г.В. Волгина, Н.Л. Козловская, Д.Ю. Щекочихин. М., 2014.

28. Fliser D., Laville M., Covic A., Fouque D., Vanholder R., Juillard L.,Biesenet W.V.European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy. The ad-hoc working group of ERBP: Nephrol Dial Transplant. 2012; 27 (12): 4263–4272. DOI:10.1093/ndt/gfs375.

29. Newhouse J.H., Kho D., Rao Q.A., Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. Am. J. Roentgenol. 2008; 191 (2): 376–382. DOI:10.2214/AJR.07.3280.

30. Kwasa E.A., Inayak S., Armstrong R. The role of inflammation in contrast-induced nephropathy. Br. J. Radiol. 2014; 87: 2–5. DOI:10.1259/bjr.20130738.

31. Aurelio A., Durante A. Contrast-Induced Nephropathy in Percutaneous Coronary Interventions: Pathogenesis, Risk Factors, Outcome, Prevention and Treatment. Cardiology. 2014; 128 (1): 62–72. DOI:10.1159/000358042.

32. Persson P.B., Hansell P., Liss P. Pathophysiology of contrast medium induced nephropathy. Kidney Int. 2005; 68: 14–22. DOI: 10.1111/j.1523-1755.2005.00377.x.

33. Thomsen H.S. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) Guidelines. Br. J Radiol. 2003; 76 (908): 513–518. DOI: 10.1259/bjr/26964464.

34. Kappel J. Safe drug prescribing for patients with renal insufficiency. Nephrology. 2002; 166: 473–477.

35. Heinrich M.C., KuhlmannM.K., Grgic A., Heckmann M., Kramann B., Uder M. Cytotoxic effects of ionic highosmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology. 2005; 235 (3): 843–849. DOI: 10.1148/radiol.2353040726.

36. Aspelin P., Aubry P., Fransson S.-G., Strasser R., Willenbrock R., Berg K.J. Nephrotoxic effects in high-risk patients undergoing angiography. New Engl. J. Med. 2003; 348 (6); 491–499. DOI: 10.1056/NEJMoa021833.

37. Taliercio C.P., Vlietstra R.E., Ilstrup D.M., Burnett, J.C., Menke K.K., Stensrud S.L., Holmes, D.R. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J. Am. Coll. Cardiol. 1991; 17 (2): 384–390. DOI.org/10.1016/S0735-1097(10)80103-2.

38. Barrett B.J., Carlisle E.J. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology. 1993; 188 (1): 171–178. DOI: 10.1148/radiology.188.1.8511292.

39. Heinrich M.C., HaberleL., Muller V., Bautz W., Uder M. Nephrotoxicity of isoosmolariodixanol compared with nonionic low-osmolar contrast media: meta- analysis of randomized controlled trials. Radiology. 2009; 250 (1): 68–86. DOI: 10.1148/radiol.2501080833.

40. Solomon R.J., Natarajan M.K., Doucet S., Sharma S.K., Staniloae C.S., Katholi R.E., Gelormini J.L., Labinaz M., Moreyra A.E. Cardiac angiography in renallyimpaired patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007; 115 (25): 3189–3196. DOI: 10.1161/CIRCULATIONAHA.106.671644.

41. Reed M., Meier P., TamhaneU.U., Welch K.B., Moscucci M., GurmH.S. The relative renal safety of iodixanol compared with low-osmolarcontrastmedia: ametaanalysis of randomized controlled trials. JACC: Cardiovasc. Interv. 2009; 2 (7): 645–654. DOI: 10.1016/j.jcin.2009.05.002.

42. Bolognese L., Falsini G., Schwenke C., Grotti S., Limbruno U., Liistro F., Carrera A., Angioli P., Picchi A., Ducci K., Pierli C. Impact of isoosmolar versus lowosmolar contrast agents on contrastinduced nephropathy and tissue reperfusion in unselected patients with STsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following primary Angioplasty for Acute Myocardial Infarction [CONTRASTAMI]

43. trial). Am. J. Cardiol. 2012; 109 (1): 67–74. DOI: 10.1016/j.amjcard.2011.08.006.

44. Dong M., Jiao Z., Liu T., Guo F., Li G. Effect of administration route on the renal safety of contrast agents: meta-analysis of randomized controlled trials. J. Nephrol. 2012; 25 (3): 290–301. DOI: 10.5301/jn.5000067.

45. Bruce R.J., Djamali A., Shinki K., Michel S.J., Fine J.P., Pozniak M.A. Background fluctuation of kidney function versus contrast-induced nephrotoxicity. Am. J. Roentgenol. 2009; 192 (3): 711–718. DOI: 10.2214/AJR.08.1413.

46. Solomon R., Deray G. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int. 2006; 100: 51–53. DOI: 10.1038/sj.ki.5000375.

47. Hou S.H., Bushinsky D.A., Wish J.B., Cohen J.J., Harrington J.T. Hospital acquired renal insufficiency: A prospective study. Am. J. Med. 1983; 74: 243–248. DOI: 10.1016/0002-9343(83)90618-6 •

48. Katholi R.E., Woods W.T. Jr, Taylor G.J., Deitrick C.L., Womack K.A., Katholi C.R., McCann W.P. Oxygen free radicals and contrast nephropathy. Am. J. Kidney Dis. 1998; 32: 64–71. DOI: 10.1053/ajkd.1998.v32.pm9669426.

49. Mehran R., Nikolsky E. Contrast induced nephropathy: Definition, epidemiology, and patients at risk. Kidney Int. Suppl. 2006: 11–15. DOI: 10.1038/sj.ki.5000368.

50. McCullough P.A., Adam A., Becker C.R., Davidson C., Lameire N., Stacul F., Tumlin J. CIN Consensus Working Panel. Risk prediction of contrastinduced nephropathy. Am. J. Cardiol. 2006; 98: 27–36. DOI: 10.1016/j.amjcard.2006.01.022.

51. Mehran R., Aymong E.D., Nikolsky E., Lasic Z., Iakovou I., Fahy M.,Mintz G.S., Lansky A.J., Moses J.W., Stone G.W., Leon M.B., Dangas G.A simple risk score for prediction of contrastinduced nephropathy after percutaneous coronary intervention: Development and initial validation. J. Am. Coll. Cardiol. 2004; 44: 1393–1399. DOI: 10.1016/j.jacc.2004.06.068.

52. Toprak O., Cirit M., Yesil M., Byrne D.W., Postaci N., Bayata S., Majchrzak K.M.,Esi E. Metabolic syndrome as a risk factor for contrast-induced nephropathy in nondiabetic elderly patients with renal impairment. Kidney Blood Press. Res. 2006; 29: 2–9. DOI: 10.1159/000092481.

53. Toprak O. Conflicting and new risk factors for contrastinduced nephropathy. J. Urol. 2007; 178 (6): 2277–2283. DOI: 10.1016/j.juro.2007.08.054.

54. Toprak O., Cirit M., Yesil M., Bayata S., Tanrisev M., Varol U., Ersoy R., Esi E. Impact of diabetic and prediabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. Nephrol. Dial. Transplant. 2007; 22: 819. DOI: 10.1093/ndt/gfl636.

55. Chang C.F., Lin C.C. Current concepts of contrast-induced nephropathy: A brief review. J. Chine. Med. Assoc. 2013; 76: 673–681. DOI: 10.1016/j.jcma.2013.08.011.

56. Berns A.S. Nephrotoxicity of contrast media. Kidney Int. 1989; 36: 730–740.

57. Rudnick M.R., Goldfarb S., Tumlin J. Contrast-induced nephropathy: is the picture any clearer? Clin. J. Am. Soc. Nephrol. 2008; 3: 261–262. DOI: 10.2215/CJN.04951107.

58. Lameire N., Adam A., Becker C.R., Davidson C., McCullough P.A., Stacul F., Tumlin J. Baseline Renal Function Screening. Am. J. Cardiol. 2006; 98 (6A): 21–26. DOI: 10.1016/j.amjcard.2006.01.021.

59. Gleeson T.G., Bulugahapitiya S. Contrast-induced nephropathy. Am. J. Roentgenol. 2004; 183 (6): 1673–1689. DOI: 10.2214/ajr.183.6.01831673.

60. Yaribeygi H., Farrokhi F.R., Rezaee R, Sahebkar A. Oxidative stress induces renal failure: A review of possible molecular pathways. J. Cell. Biochem. 2018; 119 (4): 2990–2998. DOI: 10.1002/jcb.26450.

61. Okamura D.M., Pennathur S., Pasichnyk K., López-Guisa J.M., Collins S., Febbraio M., Heinecke J., Eddy A.A. CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD. J. Am. Soc. Nephrol. 2009; 20 (3): 495–505. DOI: 10.1681/ASN.2008010009.

62. Mueller C. Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int. 2006; 69: 16–19. DOI: 10.1001/jama.291.19.2328.

63. Balemans C.E., Reichert L.J., van Schelven B.I., van den Brand J.A., Wetzels J.F. Epidemiology of contrastmaterialinduced nephropathy in the era of hydration. Radiology. 2012; 263 (3): 706–713. DOI: 10.1148/radiol.12111667.

64. Andersen K.J., Christensen E. I., Vik H. Effects of iodinated x-ray contrast media on renal epithelial cells in culture. Invest. Radiol. 1994; 29: 955–962.

65. Thomsen H.S. Guidelines for contrast media from the European Society of Urogenital Radiology. Am. J. Roentgenol. 2003; 181 (6): 1463–1471. DOI: 10.1097/MOU.0b013e328011c96f.

66. Ellis J.H., Cohan R.H. Prevention of contrast-induced nephropathy: an overview. Radiol. Clin. N. Am. 2009; 47 (5): 801–811. DOI: 10.1016/j.rcl.2009.06.003.

67. Solomon R., DauermanH.L. Contrast-induced acute kidney injury. Circulation. 2010; 122 (23): 2451–2455. DOI: 10.1161/CIRCULATIONAHA.110.953851.

68. Merten G.J., Burgess W.P., Gray L.V., Holleman J.H., Roush T.S., Kowalchuk G.J., Bersin R.M., Van Moore A., Simonton C.A. 3rd, Rittase R.A., Norton H.J., Kennedy T.P. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. J. Am. Med. Assoc. 2004; 291 (19): 2328–2334. DOI: 10.1001/jama.291.19.2328.

69. Masuda M., Yamada T., Mine T., Morita T., Tamaki S., Tsukamoto Y., Okuda K., Iwasaki Y., Hori M., Fukunami M. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am. J. Cardiol. 2007; 100 (5): 781–786. DOI: 10.1016/j.amjcard.2007.03.098.

70. Jang J.S., Jin H.Y., Seo J.S., Yang T.H., Kim D.K., Kim T.H., Urm S.H., Kim D.S., Kim D.K., Seol S.H., Kim D.I., Cho K.I., Kim B.H., Park Y.H., Je H.G., Ahn J.M., Kim W.J., Lee J.Y., Lee S.W. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury – a systematic review and meta-analysis. Circulation J. 2012; 76 (9): 2255–2265. DOI:10.1253/circj.CJ-12-0096.

71. Tamura A., Goto Y., Miyamoto K., Naono S., Kawano Y., Kotoku M., Watanabe T., Kadota J. Efficacy of singlebolus administration of sodium bicarbonate to prevent contrast induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure. Am. J. Cardiol. 2009; 104 (7): 921–925. DOI:10.1016/j.amjcard.2009.05.034.

72. Brar S.S., Hiremath S., Dangas G., Mehran R., Brar S.K., Leon M.B. Sodium bicarbonate for the prevention of contrast-inducedacute kidney injury: a systematic review and metaanalysis. Clin. J. Am. Soc. Nephrol. 2009; 4 (10): 1584–1592. DOI: 10.2215/CJN.03120509.

73. Vasheghani-Farahani A., Sadigh G., KassaianS.E., Khatami S.M., Fotouhi A., Razavi S.A., Mansournia M.A., Yamini-Sharif A., Amirzadegan A., Salarifar M., Sadeghian S., Davoodi G., Borumand M.A., Esfehani F.A., Darabian S. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled

74. trial. Am. J. Kidney Dis. 2009; 54 (4): 610–618. DOI: 10.1053/j.ajkd.2009.05.016.

75. Gleeson T.G., Bulugahapitiya S. Contrast-induced nephropathy. Am. J. Roentgenol. 2004; 183 (6): 1673–1689. DOI: 10.2214/ajr.183.6.01831673.

76. Heyman S.N., Rosen S., Khamaisi M., Idee J.-M., Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Invest. Radiology. 2010; 45 (4): 188–195. DOI: 10.1097/RLI.0b013e3181d2eed8.

77. Lee H.-C., Sheu S.-H., Liu I.-H., Lee C.-C., Hsieh C.-C., Yen H.-W., Lai W.-T., Chang J.-G. Impact of short-duration administration of N-acetylcysteine, probucol and ascorbic acid on contrast-induced cytotoxicity. J. Nephrol. 2012; 25 (1): 56–62. DOI: 10.5301/JN.2011.7741.

78. Briguori C., Colombo A., Violante A., Balestrieri P., Manganelli F., Elia P.P., Golia B., Lepore S., Riviezzo G., Pierfranco R., Scarpato P., Focaccio A., LibreraM., Bonizzoni E., Ricciardelli B. Standard vs. double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur. Heart J. 2004; 25 (3): 206–211. DOI: 10.1016/j.ehj.2003.11.016.

79. Tepel M., Giet M., Schwarzfeld C., Laufer U., Liermann D., Zidek W. Prevention of radiographic-contrastagentinduced reductions in renal function by acetylcysteine. New Engl. J. Med. 2000; 343 (3): 180–184. DOI:10.1056/NEJM200007203430304.

80. Ferrario F., Barone M.T., Landoni G., Genderini A., Heidemperger M., Trezzi M., Piccaluga E., Danna P., Scorza D. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy – a randomized controlled study. Nephrol. Dialysis Transplant. 2009; 24 (10): 3103– 3107. DOI: 10.1093/ndt/gfp306.

81. Alexopoulos E., Spargias K., Kyrzopoulos S., Manginas A., Pavlides G., Voudris V., Lerakis S., McLean D.S., Cokkinos D.V. Contrastinducedacute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic lowosmolar versus iso-osmolar contrast media. Am. J. Med. Scie. 2010; 339 (1): 25–30. DOI: 10.1097/MAJ.0b013e3181c06e70.

82. Boscheri A., Weinbrenner C., Botzek B., Reynen K., Kuhlisch E., Strasser R.H. Failure of ascorbic acid to prevent contrast media induced nephropathy in patients with renal dysfunction. Clin. Nephrol. 2007; 68 (5): 279–286.


Для цитирования:


Хохлов А.Л., Кабанов А.В., Козлова О.Г. Рентгеноконтрастные вещества: фокус на безопасность. Медицинская визуализация. 2018;(5):94-105. https://doi.org/10.24835/1607-0763-2018-5-94-105

For citation:


Khokhlov A.L., Kabanov A.V., Kozlova O.G. X-ray contrast media: focus on safety. Medical Visualization. 2018;(5):94-105. (In Russ.) https://doi.org/10.24835/1607-0763-2018-5-94-105

Просмотров: 114


ISSN 1607-0763 (Print)
ISSN 2408-9516 (Online)